Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P797 | ISIN: US65487U1088 | Ticker-Symbol:
NASDAQ
06.06.25 | 17:04
1,880 US-Dollar
+2,73 % +0,050
1-Jahres-Chart
NKARTA INC Chart 1 Jahr
5-Tage-Chart
NKARTA INC 5-Tage-Chart

Aktuelle News zur NKARTA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
NKARTA Aktie jetzt für 0€ handeln
15:59Nkarta CMO David Shook Steps Down, Shawn Rose To Succeed-
15:17Nkarta, Inc. - 8-K, Current Report1
14:54Nkarta, Inc.: Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus167SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat...
► Artikel lesen
15.05.Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space1
15.05.Nkarta stock rating downgraded at William Blair to Market Perform1
14.05.Nkarta, Inc. - 10-Q, Quarterly Report2
14.05.Nkarta, Inc. - 8-K, Current Report1
14.05.Nkarta, Inc.: Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights1.276Enrollment open in investigator-sponsored trial (IST) of NKX019 in myasthenia gravis; Ntrust-1, Ntrust-2, and IST of NKX019 in systemic lupus erythematosus remain open to enrollment Ntrust-1 expanded...
► Artikel lesen
27.03.Why Is Autoimmune Disease Focused Nkarta Stock Trading Higher On Thursday?4
27.03.Nkarta to lay off staff, senior leadership, in bid to advance autoimmune cell therapy4
27.03.Stifel cuts Nkarta stock price target to $14, maintains buy rating3
27.03.H.C. Wainwright maintains Buy on Nkarta stock with $18 target3
27.03.Nkarta lays off 3rd of staff, including CFO, to fund autoimmune CAR NK program3
27.03.Stifel cuts NKTX stock price target to $14, maintains buy rating2
26.03.Nkarta GAAP EPS of -$0.35 beats by $0.063
26.03.Nkarta, Inc. - 10-K, Annual Report1
26.03.Nkarta, Inc. - 8-K, Current Report2
26.03.Nkarta, Inc.: Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights379Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseasesInitial data for NKX019 in multiple autoimmune...
► Artikel lesen
02.01.Nkarta, Inc. - S-8, Securities to be offered to employees in employee benefit plans3
27.06.24Nkarta, Inc.: Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications192Patient screening underway in Ntrust-1, the first U.S.-based clinical trial of an engineered NK cell therapy for the treatment of lupus nephritis IND cleared for Ntrust-2, a clinical trial for NKX019...
► Artikel lesen
20 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1